Business
NeuroOne(R) Appoints David Wambeke as Chief Business Officer; Concurrently Completes Insider Purchase of 1 Million Shares
Proven Healthcare Leader with Capital Markets Expertise to Support Strategic Expansion; Personal Investment Signals Strong Conviction in Company's Strategic Growth EDEN PRAIRIE, MINN. - March 3, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Cor...
About this update from Neuroone Medical Technologies Corporation
[{"type":"image","caption":"","headline":"NeuroOne(R) Appoints David Wambeke as Chief Business Officer; Concurrently Completes Insider Purchase of 1 Million Shares","size":{"original":{"width":140,"height":70,"url":"https://media.zenfs.com/en/newsmediawire_165/6e29368af07e7c003454bc6560423ba4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/61CM7UIIJoR34ZjwWwyL7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6e29368af07e7c003454bc6560423ba4","width":140,"height":70}}},{"type":"text","content":"Proven Healthcare Leader with Capital Markets Expertise to Support Strategic Expansion; Personal Investment Signals Strong Conviction in Company's Strategic Growth","length":167,"tagName":"p"},{"type":"text","content":"EDEN PRAIRIE, MINN. - March 3, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced that David Wambeke has joined the Company as Chief Business Officer and concurrently purchased 1,000,000 shares of NeuroOne common stock.","length":433,"tagName":"p"},{"type":"text","content":"Mr. Wambeke will lead NeuroOne's drug delivery program and work closely with the executive team to advance the Company's clinical development and commercialization strategy. His responsibilities will include refining product requirements for preclinical and clinical-stage devices, expanding relationships with key opinion leaders in targeted disease areas, and engaging prospective pharmaceutical partners to maximize the strategic value of the Company's emerging drug delivery platform.","length":500,"tagName":"p"},{"type":"text","content":"Mr. Wambeke will also oversee investor relations, strengthening the Company's market communication and broadening engagement with the investment community. Additionally, he will support strategic business development initiatives, including partnerships and other strategic corporate transactions.","length":300,"tagName":"p"},{"type":"text","content":""David brings a rare combination of public company experience, capital markets expertise, and a demonstrated ability to translate strategic vision into operational and clinical execution," said Dave Rosa, CEO ...